Postoperative Pain in Orthopaedics
Conditions
Brief summary
The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for Postoperative analgesia in orthopaedics. To explore the reasonable dosage of HRS-2129 for Postoperative analgesia in orthopaedics.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
1. Able and willing to provide a written informed consent 2. Subjects requiring elective orthopedic surgery 3. Conform to the ASA Physical Status Classification
Exclusion criteria
1. Subjects with a history of severe allergies 2. Subjects with nervous system disease 3. Subjects with a history of mental illness 4. Subjects with abnormal liver and renal function 5. Subjects with poorly controlled hypertensive or hypotensive 6. QTc:\>450ms(male),\>470ms(female) 7. Subjects who screened positive for substance abuse 8. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s) 9. The investigators determined that other conditions were inappropriate for participation in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety:Incidence and severity of AE/SAE | from ICF signing date to day 12 since last dose(14 days) |
Secondary
| Measure | Time frame |
|---|---|
| the Sum of Pain Intensity Differences in Pain Score Over 6hour、12hour、16hour、24hour、48hour、12hour-24hour、24hour-48hour under static and moving condition | 48hours |
| The response rate of NRS scores under static and moving condition at 24hour and 48hour after the first dose of medication | 48hours |
| Participant ' satisfaction score for analgesia treatment | 48hours |
| Investigator satisfaction score for analgesia treatment | 48hours |
| Time of first use of remedial analgesic medication | 48hours |
| Cumulative use of remedial analgesics | 48hours |
| Cmax | 5 days |
| Tmax | 5 days |
| AUC0-12h | 5 days |
Countries
China